MDR1/P-glycoprotein in haematological neoplasms

European Journal of Cancer

Volumn 32, Issue 6, 1996, Pages 1034-1038

  Marie, J P ^a   Zhou, D C ^a   Gurbuxani, S ^a   Legrand, O ^a   Zittoun, R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN P; MESSENGER RNA; MONOCLONAL ANTIBODY; PROTEIN BCL 2;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CHEMOTHERAPY; CHILDHOOD CANCER; CHRONIC LYMPHATIC LEUKEMIA; DRUG TRANSPORT; HUMAN; HUMAN CELL; HUMAN TISSUE; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; MYELODYSPLASIA; NONHODGKIN LYMPHOMA; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA; LYMPHOMA, NON-HODGKIN; MULTIPLE MYELOMA; NEOPLASM PROTEINS; P-GLYCOPROTEIN;

EID: 0029894447     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(96)00055-X     Document Type: Article

References (81)

1. Chaudhary P, Roninson I. Expression and activity of the multidrug resistance Pgp in human peripheral blood lymphocytes. Blood 1992, 80, 2735-2741.
2. Neyfakh A, Serpinskaya A, Chervonsky A, Apasov S, Karazov A. Multidrug-resistance phenotype of a subpopulation of T-lymphocytes without drug selection. Exp Cell Res 1989, 185, 496-500.
3. Drach D, Zhao S, Drach J, et al. Subpopulation of normal peripheral blood and bone marrow cells express a functional multidrug resistance phenotype. Blood 1992, 80, 2729-2733.
4. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994, 83, 2451-2458
5. Kuwazuru Y, Hanada S, Furukawa T, et al. Expression of P-glycoprotein in adult T-cell leukemia cells. Blood 1990, 10, 2065-2071.
6. Pasman P, Schouten H. Multidrug resistance mediated by P-glycoprotein in haematological malignancies. Neth J Med 1993, 42, 218-231.
7. Licht T, Pastan I, Gottesman M, Herrmann F. P-glycoprotein mediated multidrug resistance in normal and neoplastic haematopoietic cells. Annals Hematol 1994, 69, 159-171.
8. Nooter K, Sonneveld P. Clinical relevance of p-glycoprotein expression in haematological malignancies. Leuk Res 1994, 18, 233-243.
9. Marie JP. P-glycoprotein in adult hematological malignancies. Hematol Oncol Clin N Am 1995, 9, 239-250.
10. Herzog C, Trepel J, Mickley L, Bates S, Fojo A. Various methods of analysis of MDR 1/P-glycoprotein in human colon cancer cell lines. J Natl Cancer Inst 1992, 84, 711-716.
11. Brophy NA, Marie JP, Rojas VA, et al. Mdr 1 gene expression in childhood acute lymphoblastic leukemias and lymphomas - a critical evaluation by four techniques. Leukemia 1994, 8, 327-335.
12. Wall D, Sparrow R, Hu X, et al. Clinical application of a rapid, functional assay for multidrug resistance based on accumulation of a fluorescent dye, Fluo-3. Eur J Cancer 1993, 29A, 1024-1027.
13. Longo RBL, Vecchi A, Messora C, Sacchi S. P-glycoprotein expression in acute myeloblastic leukemia analyzed by immunocytochemistry and flow cytometry. Leuk Lymphoma 1995, 17, 121-125.
14. Gala JLM, Bell DR, Michaux JL, Ma DDF. Specificity and sensitivity of immunocytochemistry for detecting P-glycoprotein in haematological malignancies. J Clin Pathol 1994, 47, 619-624.
15. - cases. Blood 1995, 86, 2329-2342.
16. Bailly JD, Muller C, Jaffrézou J-P, et al. Lack of correlation between expression and function of P-glycoprotein in acute myeloid leukemia cell lines. Leukemia 1995, 9, 799-807.
17. Ross D, Wooten P, Sridhara R, Ordonez J, Lee E, Schiffer S. Enhancement of daunorubicin accumulation, retention and cytotoxicity by verapamil and cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood 1993, 82, 1288-1299.
18. Marie J, Faussat-Suberville A, Zhou D, Zittoun R. Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr 1 expression. Leukemia 1992, 7, 825-832.
19. Müller M, Lennartz K, Nowrousian M, et al. Improved flow-cytometric detection of low P-glycoprotein expression in leukaemic blast by histogram subtraction analysis. Cytometry 1994, 15, 64-72.
20. Zhou D, Marie J, Suberville A, Zittoun R. Relevance of MDR-1 gene expression in acute myeloid leukemia and comparison of different diagnostic methods. Leukemia 1992, 6, 879-885.
21. Miyachi H, Takemura Y, Yonekura S, et al. MDR1 (multidrug resistance) gene expression in adult acute leukemia: correlations with blast phenotype. Int J Hematol 1993, 57, 31-37.
22. Paietta E, Anderson J, Racevskis J, et al. Significantly lower P-glycoprotein expression in acute promyelocytic leukemia than in other types of acute myeloid leukemia: immunological, molecular and functional analyses. Leukemia 1994, 8, 968-973.
23. Drach D, Zhao S, Drach J, Andreeff M. Low incidence of MDR1 expression in acute promyelocytic leukemia. Br J Hematol 1995, 90, 369-374.
24. Te Boekhorst P, de Leeuw K, Schoester M, et al. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ since myeloid leukemia cells. Blood 1993, 82, 3157-3162.
25. Campos L, Guyotat D, Archimbaud E, et al. Clinical significance of multidrug resistance P-glycoprotein expression on acute non-lymphoblastic leukemia cells at diagnosis. Blood 1992, 79, 473-476.
26. Lamy T, Goasguen J, Mordelet E, et al. P-glycoprotein (P-170) and CD34 expression in adult acute myeloid leukemia (AML). Leukemia 1994, 8, 1879-1883.
27. Wood P, Burgess R, MacGregor A, Liu Yin J. P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol 1994, 87, 509-514.
28. Holmes J, Jacobs A, Carter G, Janowska-Wieczorek A, Padua R. Multidrug resistance in haematopoietic cell lines, myelodysplastic syndromes and acute myeloblastic leukaemia. Br J Haematol 1989, 72, 40-44.
29. List A, Spier C, Cline A, et al. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Br J Haematol 1991, 78, 28-34.
30. Sonneveld P, Van Dongen J, Hagemeijer A, et al. High expression of multidrug resistance P-glycoprotein in high-risk myelodysplasia is associated with immature phenotype. Leukemia 1993, 7, 963-969.
31. Lepelley P, Soenen V, Preudhomme C, Lai J, Cosson A, Fenaux P. Expression of the multidrug resistance P-glycoprotein and its relationship to hematological characteristics and response to treatment in myelodysplastic syndromes. Leukemia 1994, 8, 998-1004.
32. Holmes J, West R. The effect of MDR1 gene expression on outcome in acute myeloblastic leukaemia. Br J Cancer 1994, 69, 382-384.
33. Kuwazuru Y, Yoshimura A, Hanada S, et al. Expression of the multidrug transporter P-glycoprotein in acute leukemia cells and correlation to clinical drug resistance. Cancer 1990, 66, 868-873.
34. Marie J, Zittoun R, Sikic B. Multidrug resistance (mdr) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991, 78, 586-592.
35. Pirker R, Wallner J, Geissler K, et al. MDR-1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991, 83, 708-712.
36. Michieli M, Damiani D, Geromin A, et al. Overexpression of multidrug resistance-associated p-170 glycoprotein in acute non-lymphocytic leukemia. Eur J Haematol 1992, 48, 87-92.
37. Tirikainen M, Elonen E, Ruutu T, Jansson S, Krusius T. Clinical significance of P-glycoprotein expression in acute leukaemia as analysed by immunocytochemistry. Eur J Haematol 1993, 50, 279-285.
38. Zöchbauer S, Gsur A, Brunner R, Kyrle P, Lechner K, Pirker R. P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. Leukemia 1994, 8, 975-977.
39. Basara N, Radosevic-Radojkovic N, Colovic M, Boskovic D, Rolovic Z. In vitro drug sensitivity of leukemic progenitors and P-glycoprotein expression in adult myeloid leukemia: correlation with induction treatment outcome. Eur J Haematol 1995, 55, 83-87.
40. Zhou D, Zittoun R, Marie J. Expression of multidrug resistance-associated protein (MRP) and multidrug resistance (MDR1) genes in acute myeloid leukemia. Leukemia 1995, 9, 1661-1666.
41. Sato H, Preisler H, Day R, et al. MDR1 transcript levels as an indication of resistant disease in acute myelogenous leukemia. Br J Haematol 1990, 75, 340-345.
42. Gruber A, Vitols S, Norgren S, et al. Quantitative determination of mdr1 gene expression in leukaemic cells from patients with acute leukaemia. Br J Cancer 1992, 66, 266-272.
43. Ino T, Miyazaki H, Isogai M, et al. Expression of P-glycoprotein in de novo acute myelogenous leukemia at initial diagnosis: results of molecular and functional assays, and correlation with treatment outcome. Leukemia 1994, 8, 1492-1497.
44. Cole S, Bhardwaj G, Gerlach J, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992, 258, 1650-1654.
45. Abbaszadegan M, Futscher B, Klimecki W, List A, Dalton W. Analysis of multidrug resistance associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res 1994, 54, 4676-4679.
46. Hart S, Ganeshaguru K, Hoffbrand A, Prentice H, Metha A. Expression of the multidrug resistance associated protein (MRP) in acute leukemia. Leukemia 1994, 8, 2163-2168.
47. Schneider E, Cowan K, Ader H, et al. Increased expression of the multidrug resistance-associated protein gene in relapsed leukemia. Blood 1995, 85, 186-193.
48. Nooter K, Westerman A, Flens M, et al. Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1995, 1, 1301-1310.
49. Delmer A, Marie J, Thevenin D, Cadiou M, Viguié F, Zittoun R. Multivariate analysis of prognostic factors in acute myeloid leukemia: value of clonogenic leukemic cell properties. J Clin Oncol 1989, 7, 738-746.
50. Schuurhuis G, Broxterman H, Ossenkoppele G, et al. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 and MRP together with 1-beta-D-arabinosylcytosine sensitivity may predict clinical response in acute myeloid leukemia. Clin Cancer Res 1995, 1, 81-93.
51. Campos L, Rouault J, Sabido O, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993, 81, 3091-3096.
52. Miwa H, Kita K, Nishii K, et al. Expression of MDR1 gene in acute leukemia cells: association with CD7+ acute myeloblastic leukemia/acute lymphoblastic leukemia. Blood 1993, 82, 3445-3451.
53. Goasguen J, Dossot J, Fardel O, et al. Expression of the multidrug resistance P-glycoprotein (P-170) in 59 de novo acute lymphoblastic leukemia: prognostic implications. Blood 1993, 81, 2394-2398.
54. Sauerbrey A, Zintl F, Volm M. P-glycoprotein and glutathione S-transferase pi in childhood acute lymphoblastic leukaemia. Br J Cancer 1994, 70, 1144-1149.
55. Rothenberg M, Mickley L, Cole D, et al. Expression of the mdr1/P-gp gene in patients with acute lymphoblastic leukemia. Blood 1989, 74, 1388-1395.
56. Fenneteau O, Marie J, Lescoeur B, Vilmer E, Schlegel N. Expression of the multidrug resistance P-glycoprotein (P-170) in acute lymphoblastic leukemia. Blood 1993, 82, 3787.
57. Ubezio P, Limonta M, D'Incalci M, et al. Failure to detect the P-glycoprotein multidrug resistant phenotype in cases of resistant childhood acute lymphoblastic leukemia. Eur J Clin Oncol 1989, 25, 1895-1899.
58. Goldstein L, Galski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989, 29, 116-124.
59. Tawa A, Ishihara S, Yumura K, et al. Expression of the multidrug-resistance gene in childhood leukemia. Jpn J Ped Hematol 1990, 4, 38-43.
60. Pieters R, Hongo T, Loonen A, et al. Different types of non-P-glycoprotein mediated multiple drug resistance in children with relapsed acute lymphoblastic leukemia. Br J Cancer 1992, 65, 691-697.
61. Gekeler V, Frese G, Noller A, et al. Mdr1/P-glycoprotein, topoisomerase, and glutathione-S transferase pi gene expression in primary and relapsed state adult and childhood leukemias. Br J Cancer 1992, 66, 507-517.
62. Beck J, Handgretinger R, Dopfer R, Klingebiel T, Niethammer D, Gekeler V. Expression of mdr1, mrp, topoisomerase IIα/β and cyclin A in primary or relapsed states of acute lymphoblastic leukemia. Br J Haematol 1995, 89, 356-363.
63. Pieters R, Huismans D, Loonen A, et al. Relation of cellular drug resistance to long term clinical outcome in childhood acute lymphoblastic leukemia. Lancet 1991, 338, 399-403.
64. Dalton W, Grogan T, Rybski J, et al. Immmunohistochemical detection and quantification of P-glycoprotein in multiple drug resistant human myeloma cells: associated with level of drug resistance and drug accumulation. Blood 1989, 73, 747-752.
65. Ishikawa H, Kawano M, Okada K, et al. Expression of DNA topoisomerase I and II and the genes possibly related to drug resistance in human myeloma cells. Br J Haematol 1993, 83, 68-73.
66. Petrini M, Di Simone D, Favati A, Matth L, Valentini P, Grassi B. GST-pi and P-gp co-expression in multiple myeloma. Br J Haematol 1995, 90, 393-397.
67. Grogan T, Spiers C, Salmon S, et al. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy. Blood 1993, 81, 490-495.
68. Sonneveld P. Biology and treatment of resistance in multiple myeloma. In Dammacco F, Barlogie B, eds. Multiple Myeloma and Related Disorders. Rome, Italy, Ares-Serono Symposia Publications, 1994, 107-114.
69. Epstein J, Xiao H, Oba B. P-glycoprotein expression in plasma cell myeloma is associated with resistance to VAD. Blood 1989, 74, 913-917.
70. Sonneveld P, Durie B, Lokhorst HM, et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. Lancet 1992, 340, 255-259.
71. Scheffer GL, Winjgaard PLJ, Flens MJ, et al. The drug resistance-related protein LRP is the human major vault protein. Nature Medicine 1995, 1, 578-582.
72. Marie J, Simonin G, Legrand O, et al. Glutathione-S-transferases π, α, μ mRNA expression in normal lymphocytes and chronic lymphocytic leukemia. Leukemia 1995, 9, 1742-1747.
73. Holmes J, Jacobs A, Carter G, Whittaker J, Bentley D, Padua R. Is the mdr1 gene relevant in chronic lymphocytic leukemia? Leukemia 1990, 4, 216-217.
74. Chabner B, Bates S, Fojo A, Spolyar M, Wilson W. Drug resistance in adult lymphomas. Semin Hematol 1994, 31, 70-87.
75. Yuen A, Sikic B. Multidrug resistance in lymphomas. J Clin Oncol 1994, 12, 2453-2459.
76. Schlaifer D, Laurent G, Chittal S, et al. Immunohistochemical detection of multidrug resistance associated P-glycoprotein in tumour and stromal cells of human cancers. Br J Cancer 1990, 62, 177-182.
77. Kang Y, Zhan Z, Regis J, et al. Expression of mdr1 in refractory lymphoma: quantitation by polymerase chain reaction and validation of the assay. Blood 1995, 86, 1515-1524.
78. Cheng A, Su I, Chen Y, Lee T, Wang C. Expression of P-glycoprotein and glutathione-S transferase in recurrent lymphomas: the possible role of Epstein-Barr virus, immunopheno-types, and other predisposing factors. J Clin Oncol 1993, 11, 109-115.
79. Pileri S, Sabattini E, Falini B, et al. Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathology 1991, 19, 131-140.
80. Rodriguez C, Commes T, Robert J, Rossi J. Expression of P-glycoprotein and anionic glutathione S transferase genes in non-Hodgkin's lymphoma. Leuk Res 1993, 17, 149-156.
81. Niehans G, Jaszcz W, Brunetto V, et al. Immunohistochemical identification of P-glycoprotein in previously untreated, diffuse large cell and immunoblastic lymphomas. Cancer Res 1992, 52, 3668-3675.